Joshua Kantrowitz
Overview
Explore the profile of Joshua Kantrowitz including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
7
Citations
129
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Govani V, Shastry A, Iosifescu D, Govil P, Mayer M, Sobeih T, et al.
Res Sq
. 2023 Jun;
PMID: 37293030
Auditory cognition is impaired in schizophrenia, and typically engages a complex, distributed, hierarchical network, including both auditory and frontal input. We recently demonstrated proof of principle for the target engagement...
2.
Abi-Dargham A, Javitch J, Slifstein M, Anticevic A, Calkins M, Cho Y, et al.
Schizophr Bull
. 2021 Aug;
48(1):199-210.
PMID: 34423843
Decades of research have highlighted the importance of optimal stimulation of cortical dopaminergic receptors, particularly the D1R receptor (D1R), for prefrontal-mediated cognition. This mechanism is particularly relevant to the cognitive...
3.
Petkova E, Lu F, Kantrowitz J, Sanchez J, Lehrfeld J, Scaramello N, et al.
Compr Psychiatry
. 2014 Sep;
55(8):1862-74.
PMID: 25214372
Schizophrenia patients exhibit impairments in auditory-based social cognition, indicated by deficits in detection of prosody, such as affective prosody and basic pitch perception. However, little is known about the psychometric...
4.
Kantrowitz J, Javitt D
Curr Opin Psychiatry
. 2012 Feb;
25(2):96-102.
PMID: 22297716
Purpose Of Review: The past 20 years have seen the glutamatergic hypothesis go from theory to phase III trials of novel mechanism antipsychotics. Recent Findings: We review the recent literature...
5.
Kantrowitz J, Citrome L
Core Evid
. 2011 Jan;
2(4):261-71.
PMID: 21221191
Introduction: Paliperidone, the 9-hydroxy metabolite of risperidone, is a second-generation antipsychotic that was recently approved for the treatment of schizophrenia. It is marketed as an improvement over risperidone, but is...
6.
Kantrowitz J, Citrome L, Javitt D
CNS Drugs
. 2009 Jul;
23(8):681-91.
PMID: 19594197
Evidence for an intrinsic relationship between sleep, cognition and the symptomatic manifestations of schizophrenia is accumulating. This review presents evidence for the possible utility of GABA(B) receptor agonists for the...
7.
Citrome L, Kantrowitz J
Expert Rev Neurother
. 2008 Jul;
8(7):1079-91.
PMID: 18590478
Benefit-risk decisions are the central part of the philosophy of evidence-based medicine. Although number needed to treat (NNT) and number needed to harm (NNH) can quantify differences between two antipsychotics...